Risk Assessment in Pulmonary Hypertension: Practice Trends and Updates

ReachMD CME

#Science #Health and Well-Being #Medicine #ReachMD

43:56

On August 20th, 1989, Lyle and Erik Menendez shot and killed their own parents. Until then, this Beverly Hills family had been a portrait of the American Dream. How did it go so wrong? To listen to all four episodes of 'The Menendez Brothers' right now and ad-free, go to IntoHistory.com . Subscribers enjoy uninterrupted listening, early releases, bonus content and more, only available at IntoHistory.com . If you or someone you know is in crisis, there is free help available at mhanational.org Learn more about your ad choices. Visit megaphone.fm/adchoices…

MP3•Главная эпизода

CME credits: 1.00
Valid until: 20-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/risk-assessment-in-pulmonary-hypertension-practice-trends-and-updates/28867/
Hear about the latest updates in risk assessment and find out how you can accurately use risk stratification to categorize patients in a timely manner to improve both their care and quality of life. You’ll also discover changing practice trends and the latest evidence that may impact your practice.

462 эпизодов

ReachMD CME

Risk Assessment in Pulmonary Hypertension: Practice Trends and Updates

ReachMD CME

191 subscribers

published год назад

MP3•Главная эпизода

462 эпизодов

#Science #Health and Well-Being #Medicine #ReachMD

Все серии

ReachMD CME

1
No Patient Left Behind! Advancing CKD-Associated Pruritus Care

6 weeks назад

—

CME credits: 0.25 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-left-behind-advancing-ckd-associated-pruritus-care/26637/ Patients with chronic kidney disease-associated pruritus (CKD-aP) often face delays in diagnosis and treatment, as well as potential side effects from some prescribed medicines. Tune in as our experts dive into the burden of CKD-aP symptoms and break down the long-term outcomes and benefits of new and emerging treatments.…

ReachMD CME

1
Evaluation and Management of AKI in Cirrhosis: At the Interface of Gastroenterology and Nephrology

8 weeks назад

—

CME credits: 0.25 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/evaluation-and-management-of-aki-in-cirrhosis-at-the-interface-of-gastroenterology-and-nephrology/26988/ In patients with advanced liver disease, decompensated cirrhosis and portal hypertension can impact kidney function through development of acute kidney injury (AKI). Multiple different etiologies of AKI can be seen in cirrhotic patients, including prerenal AKI, acute tubular injury, and hepatorenal syndrome (HRS), which require different treatment approaches. This podcast will emphasize the importance of multidisciplinary care and use of established protocols in treating these patients, particularly when considering a bridge to liver transplantation, and discuss specific considerations for patients with transjugular intrahepatic portosystemic shunt (TIPS).…

ReachMD CME

1
Precision Medicine in Myasthenia Gravis: Crafting Personalized Treatment Strategies

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-myasthenia-gravis-crafting-personalized-treatment-strategies/32244/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
Optimizing FcRn Therapy: Addressing and Reducing Adverse Reactions

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-fcrn-therapy-addressing-and-reducing-adverse-reactions/32243/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
FcRn Antagonists in Myasthenia Gravis: A New Era in Targeted Therapy

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/fcrn-antagonists-in-myasthenia-gravis-a-new-era-in-targeted-therapy/32242/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
The Science Behind FcRn Antagonists: A Deep Dive Into Their Mechanism of Action

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-science-behind-fcrn-antagonists-a-deep-dive-into-their-mechanism-of-action/32241/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
Balancing Risk and Benefit: Traditional MG Treatments and Medications to Avoid

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/balancing-risk-and-benefit-traditional-mg-treatments-and-medications-to-avoid/32240/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
Autoantibodies in MG: Their Role in Diagnosis and Treatment

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-in-mg-their-role-in-diagnosis-and-treatment/32239/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
Diagnosing gMG: Navigating Current Tools and Approaches

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-gmg-navigating-current-tools-and-approaches/32238/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
Life-Threatening Events: Understanding and Preventing Myasthenic Crisis

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/life-threatening-events-understanding-and-preventing-myasthenic-crisis/32237/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
Understanding Disease Progression: The Shift From Ocular to Generalized MG

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/understanding-disease-progression-the-shift-from-ocular-to-generalized-mg/32236/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
Beyond the Symptoms: The True Impact of gMG on Patients' Lives

8 weeks назад

—

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-symptoms-the-true-impact-of-gmg-on-patients-lives/32235/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.…

ReachMD CME

1
Unique New Strategies for the Pharmacologic Treatment of Dry Eye Disease: Focus

8 weeks назад

—

CME credits: 0.75 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/unique-new-strategies-for-the-pharmacologic-treatment-of-dry-eye-disease-focus/29732/ Increased understanding of the neurobiology of dry eye disease (DED) has led to a greater emphasis on its significant and potentially serious impact on patients’ vision and quality of life. Emerging treatments for DED go beyond mere symptom management to target its neurobiology. Join an expert panel consisting of an ophthalmologist and an optometrist to discuss the burden and causes of DED, the role of the lacrimal functional unit in its pathophysiology, and the rationale for targeted neuromodulation. The panel will also explore the symptoms of DED and the new pharmacologic agents that target the LFU along with clinical evidence supporting their use. The program will also include a video vignette of a patient with DED to highlight the challenges and realities of living with DED.…

ReachMD CME

1
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices

8 weeks назад

—

CME credits: 0.25 Valid until: 15-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/maximizing-myeloma-outcomes-with-gprc5d-directed-therapy-practical-expert-case-studies-and-best-practices/29812/ This 15-minute audio podcast uses real-world patient cases to illustrate effective strategies for managing adverse events (AEs) associated with GPRC5D-directed therapies in multiple myeloma. Expert faculty discuss how to safely implement these therapies to achieve deep, durable responses while optimizing patient tolerability and quality of life. Listeners will gain insights into specific prophylaxis, dosing, and interprofessional management protocols to address unique AEs such as cytokine release syndrome, skin toxicity, and dysgeusia. This practical case-based discussion will equip healthcare professionals with actionable tools to improve outcomes for their patients with relapsed/refractory multiple myeloma.…

ReachMD CME

1
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy

8 weeks назад